Obesity has nearly tripled worldwide since 1975, now affecting over 2.6 billion people and projected to impact half the global population by 2035 . Recent research reveals that, despite lifestyle and pharmacologic interventions, durable reduction in major adverse cardiovascular events (MACE) had remained elusive—until the advent of GLP-1 receptor agonists . The SELECT trial marked a breakthrough, with semaglutide showing a 20% reduction in MACE among adults with established CVD but without diabetes. Next-generation agents like Tirzepatide now offer promise for even greater weight loss and enhanced cardioprotection.
Discover how the new era of obesity medication is reshaping cardiovascular risk management … Click Here ##Reference## Gajos G. Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment. Pol Arch Intern Med. 2025;135(3):16983.## In…
